Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial

Main Article Content

Bruce Strober
Yale University, New Haven & Central Connecticut Dermatology Research, Cromwell, CT, USA,

Akihiko Asahina
The Jikei University School of Medicine, Tokyo, Japan;

Ulrich Mrowietz
Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig- Holstein, Campus Kiel, Germany

Mark Lebwohl
Peter Foley
The University of Melbourne, St. Vincent’s Hospital Melbourne, Fitzroy and Probity Medical Research Inc., Skin Health Institute, Carlton, Victoria, Australia

Richard Langley
Division of Clinical Dermatology and Cutaneous Science, Dalhousie University, Halifax, Nova Scotia, Canada

Jonathan Barker
St John’s Institute of Dermatology, King’s College London, London, UK

Christopher Cioffi
UCB Pharma

Nancy Cross
UCB Pharma

Maggie Wang
UCB Pharma

Carle Paul
Toulouse University and CHU, Toulouse, France

Keywords

bimekizumab, psoriasis, BE BRIGHT, open label extension trial

Abstract

N/A

References

1. Adams R et al. Front Immunol 2020;11:1894;

2. Reich K et al. Lancet 2021;397:487–98; 3Gordon K et al. Lancet 2021;397:475–86; 4Warren R et al. NEJM 2021; DOI: 10.1056/NEJMoa2102388; 5Reich K et al. NEJM 2021; DOI: 10.1056/NEJMoa2102383

Article Sidebar

Poster PDF
Published
Nov 5, 2021
DOI https://doi.org/10.25251/skin.5.supp.52

Article Details

How to Cite
[1]
Strober , B., Asahina, A., Mrowietz, U., Lebwohl, M., Foley, P., Langley, R., Barker, J., Cioffi, C., Cross, N., Wang, M. and Paul, C. 2021. Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial. SKIN The Journal of Cutaneous Medicine. 5, 6 (Nov. 2021), s52. DOI:https://doi.org/10.25251/skin.5.supp.52.
Issue
Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Section
Poster Presentations from FC21 Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 9 10 11 12 13 14 15 16 17 18 > >>